Bio - for an open phI - specific cohort updates provide catalysts necessary for keeping sp stable and bumping it up slowly - as long as the news is good. If, every month, Leo pr's something like "cohort 4 participants on 4th cycle. Participant number 3 has experienced a biomarker reduction of __% since beginning treatment. The second member of this cohort has had no measurable disease progression" - then we're in great shape. And now - with Aspire and ASCO behind us - Leo can do that. He is smart enough to take advantage of this opportunity. It is part of what a phase one is all about on the companies end - regularly stirring that pot of optimism to give investors the feeling that they need to get in now.